3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine, are elevated in high-fat diet–induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon-like peptide 1. Obese Fpr1 knockout mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota. Overall, we describe a new mechanism by which the gut microbiota can modulate glucose metabolism, providing a potential approach for the treatment of metabolic disease.

          Related collections

          Author and article information

          Journal
          Diabetes
          Diabetes
          diabetes
          diabetes
          Diabetes
          Diabetes
          American Diabetes Association
          0012-1797
          1939-327X
          July 2019
          22 April 2019
          : 68
          : 7
          : 1415-1426
          Affiliations
          [1] 1Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA
          [2] 2Department of Pharmacology, University of California, San Diego, La Jolla, CA
          [3] 3Second Genome, Inc., South San Francisco, CA
          [4] 4Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA
          Author notes
          Corresponding author: Jerrold M. Olefsky, jolefsky@ 123456ucsd.edu
          Author information
          http://orcid.org/0000-0003-0392-1705
          Article
          PMC6609982 PMC6609982 6609982 1307
          10.2337/db18-1307
          6609982
          31010956
          d9f78a93-74d0-4347-811c-12f698d86329
          © 2019 by the American Diabetes Association.

          Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

          History
          : 18 December 2018
          : 08 April 2019
          Page count
          Figures: 6, Tables: 0, Equations: 0, References: 53, Pages: 12
          Funding
          Funded by: NIH Office of the Director, DOI http://dx.doi.org/http:/dx.doi.org/10.13039/100000052;
          Award ID: F32-DK-105686
          Award ID: T32-DK-007494
          Funded by: National Institute of Diabetes and Digestive and Kidney Diseases, DOI http://dx.doi.org/http:/dx.doi.org/10.13039/100000062;
          Award ID: DK-033651
          Award ID: DK-063491
          Award ID: DK-074868
          Award ID: DK-101395
          Funded by: Merck, DOI http://dx.doi.org/http:/dx.doi.org/10.13039/100004334;
          Funded by: Johnson & Johnson, DOI http://dx.doi.org/;
          Award ID: UCSD 2016-1729
          Categories
          0702
          Metabolism

          Comments

          Comment on this article